Acetate-free biofiltration reduces intradialytic hypotension: a European multicenter randomized controlled trial

Blood Purif. 2012;34(3-4):354-63. doi: 10.1159/000346293. Epub 2013 Feb 12.

Abstract

Background: Intradialytic hypotension (IH) is a common complication of bicarbonate hemodialysis (BD) and contributes to the intolerance of dialysis and the high cardiovascular morbidity and mortality among dialysis patients, the risk of which can be contained by convective therapies.

Aims/methods: To assess whether acetate-free biofiltration (AFB), a hemodiafiltration technique found to improve intradialytic cardiovascular stability in short-term studies, can influence long-term IH rates, predialysis systolic blood pressure (SBP), cardiovascular morbidity and mortality by comparison with BD, we analyzed data from a randomized controlled trial enrolling 371 new-to-dialysis patients, 194 on BD and 177 on AFB.

Results: During a 3-year follow-up, AFB carried a significantly lower risk of IH (incidence rate ratio 0.60 (95% CI 0.53-0.68), p < 0.0001). SBP dropped on AFB (p = 0.01), while it did not change on BD. Cardiovascular morbidity and mortality were similar between AFB and BD.

Conclusion: AFB carries a lower long-term IH rate and reduces SBP by comparison with BD.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bicarbonates / chemistry
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / mortality
  • Europe
  • Female
  • Hemodiafiltration / adverse effects*
  • Hemodialysis Solutions / chemistry
  • Humans
  • Hypotension / etiology*
  • Hypotension / prevention & control*
  • Male
  • Middle Aged
  • Morbidity
  • Treatment Outcome

Substances

  • Bicarbonates
  • Hemodialysis Solutions